News - OBI Pharma 台灣浩鼎

2020.Nov.19

未分類

Corporate

OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

2020.Sep.14

未分類

Corporate

OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

2020.Jun.22

未分類

Corporate

Poster Presentations at AACR 2020 Virtual Annual Meeting II

2020.Jun.16

未分類

Corporate

OBI Pharma Announces Poster Presentations at AACR 2020 Virtual Annual Meeting II

2020.May.29

未分類

Corporate

OBI Pharma Posters at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

2020.May.20

未分類

Corporate

OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

2020.Apr.08

未分類

Corporate

OBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic

2020.Jan.21

未分類

Corporate

OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

2020.Jan.09

未分類

Corporate

OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference

2019.Dec.26

未分類

Corporate

OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

Announcements

Latest announcements

Events

Latest events